156 related articles for article (PubMed ID: 3653827)
1. [Miglitol in the treatment of the insulin-dependent diabetic patient. Improved metabolic control and excellent tolerance].
Rinninger F; Lotz N; Hillebrand I; Bachmann W
Fortschr Med; 1987 Jul; 105(22):435-8. PubMed ID: 3653827
[No Abstract] [Full Text] [Related]
2. HbA(1c) and glycemic profile, basal- and post-treatment with Miglitol, in an area with a Mediterranean diet.
Faure E; Pallardo LF; Mesa J; Puig-Domingo M; García-Mayor R; Benito P; Ravella R; Artés M; López JS;
Diabetes Care; 2002 Oct; 25(10):1896-8. PubMed ID: 12351510
[No Abstract] [Full Text] [Related]
3. Effect of alpha-glucosidase inhibition on glucose profiles in insulin dependent diabetes.
Hillman RJ; Scott M; Gray RS
Diabetes Res; 1989 Feb; 10(2):81-4. PubMed ID: 2663321
[TBL] [Abstract][Full Text] [Related]
4. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
[TBL] [Abstract][Full Text] [Related]
5. Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes.
Tattersall R
Diabet Med; 1993 Oct; 10(8):688-93. PubMed ID: 8261749
[No Abstract] [Full Text] [Related]
6. Effects of alpha-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus.
Dimitriadis G; Hatziagellaki E; Alexopoulos E; Kordonouri O; Komesidou V; Ganotakis M; Raptis S
Diabetes Care; 1991 May; 14(5):393-8. PubMed ID: 2060451
[TBL] [Abstract][Full Text] [Related]
7. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Johnston PS; Feig PU; Coniff RF; Krol A; Davidson JA; Haffner SM
Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
[TBL] [Abstract][Full Text] [Related]
8. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
[TBL] [Abstract][Full Text] [Related]
9. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients.
Johnston PS; Coniff RF; Hoogwerf BJ; Santiago JV; Pi-Sunyer FX; Krol A
Diabetes Care; 1994 Jan; 17(1):20-9. PubMed ID: 8112185
[TBL] [Abstract][Full Text] [Related]
10. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.
Chiasson JL; Naditch L;
Diabetes Care; 2001 Jun; 24(6):989-94. PubMed ID: 11375358
[TBL] [Abstract][Full Text] [Related]
11. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
Scott LJ; Spencer CM
Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834
[TBL] [Abstract][Full Text] [Related]
12. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
Johnston PS; Feig PU; Coniff RF; Krol A; Kelley DE; Mooradian AD
Diabetes Care; 1998 Mar; 21(3):416-22. PubMed ID: 9540025
[TBL] [Abstract][Full Text] [Related]
13. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics.
Standl E; Schernthaner G; Rybka J; Hanefeld M; Raptis SA; Naditch L
Diabetes Res Clin Pract; 2001 Mar; 51(3):205-13. PubMed ID: 11269893
[TBL] [Abstract][Full Text] [Related]
14. alpha-Glucosidase inhibition by miglitol in NIDDM patients.
Kingma PJ; Menheere PP; Sels JP; Nieuwenhuijzen Kruseman AC
Diabetes Care; 1992 Apr; 15(4):478-83. PubMed ID: 1499461
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
[TBL] [Abstract][Full Text] [Related]
16. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.
Pagano G; Marena S; Corgiat-Mansin L; Cravero F; Giorda C; Bozza M; Rossi CM
Diabete Metab; 1995 Jun; 21(3):162-7. PubMed ID: 7556806
[TBL] [Abstract][Full Text] [Related]
17. [Alpha-glucosidase inhibitor in type 2 diabetic patients. Metabolism and body weight are favorably modified].
Fehmann HC
MMW Fortschr Med; 2001 Apr; 143(17):46. PubMed ID: 11490509
[No Abstract] [Full Text] [Related]
18. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
Heinz G; Komjati M; Korn A; Waldhäusl W
Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
[TBL] [Abstract][Full Text] [Related]
19. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
[TBL] [Abstract][Full Text] [Related]
20. [Risk of complications in the diabetic patient. Postprandial blood glucose peaks as deciding factor].
MMW Fortschr Med; 2000 Jul; 142(26-27):54-5. PubMed ID: 10929491
[No Abstract] [Full Text] [Related]
[Next] [New Search]